Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Sell
50
SLNO Quote, Financials, Valuation and Earnings
Last price:
$51.36
Seasonality move
:
21.41%
Day range:
$50.86 - $52.74
52-week range:
$41.50 - $90.32
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
25.45x
P/B ratio:
5.58x
Volume:
1.2M
Avg. volume:
2.1M
1-year change:
3.46%
Market cap:
$2.8B
Revenue:
--
EPS (TTM):
-$1.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$48.1M | $0.08 | -- | -- | $113.54 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.73% | -82.4% | $29.05 |
|
ACTU
Actuate Therapeutics, Inc.
|
-- | -$0.28 | -- | -25.25% | $25.03 |
|
AGL
Agilon Health, Inc.
|
$1.4B | -$0.13 | -3.93% | -2.84% | $0.97 |
|
MRK
Merck & Co., Inc.
|
$17B | $2.35 | 5.81% | 38.62% | $106.62 |
|
RCEL
AVITA Medical, Inc.
|
$18M | -$0.29 | -5.31% | -22.01% | $7.92 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$51.37 | $113.54 | $2.8B | -- | $0.00 | 0% | 25.45x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.44 | $29.05 | $4.6B | 17.66x | $0.00 | 0% | 4.41x |
|
ACTU
Actuate Therapeutics, Inc.
|
$7.35 | $25.03 | $170.8M | -- | $0.00 | 0% | -- |
|
AGL
Agilon Health, Inc.
|
$0.65 | $0.97 | $270.4M | -- | $0.00 | 0% | 0.05x |
|
MRK
Merck & Co., Inc.
|
$99.72 | $106.62 | $247.5B | 13.19x | $0.81 | 3.25% | 3.93x |
|
RCEL
AVITA Medical, Inc.
|
$3.50 | $7.92 | $106.7M | -- | $0.00 | 0% | 1.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
9.62% | -1.583 | 1.45% | 15.77x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ACTU
Actuate Therapeutics, Inc.
|
3.57% | -0.138 | 0.26% | 2.66x |
|
AGL
Agilon Health, Inc.
|
10.82% | -3.454 | 8.69% | 0.25x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.025 | 20.79% | 1.06x |
|
RCEL
AVITA Medical, Inc.
|
117.49% | -1.939 | 28.73% | 0.52x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLNO
Soleno Therapeutics, Inc.
|
$64.9M | $22.7M | -23.2% | -26.56% | 34.41% | $43.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ACTU
Actuate Therapeutics, Inc.
|
-- | -$5.5M | -1128.92% | -1392.96% | -- | -$6.5M |
|
AGL
Agilon Health, Inc.
|
-$75.1M | -$127.2M | -65.38% | -71.4% | -8.86% | -$34.7M |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
RCEL
AVITA Medical, Inc.
|
$13.9M | -$9.2M | -111.55% | -1112.54% | -53.65% | -$6.5M |
Soleno Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns SLNO or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of 25.76%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About SLNO or ACAD?
Soleno Therapeutics, Inc. has a consensus price target of $113.54, signalling upside risk potential of 121.02%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.05 which suggests that it could grow by 5.88%. Given that Soleno Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is SLNO or ACAD More Risky?
Soleno Therapeutics, Inc. has a beta of -3.150, which suggesting that the stock is 415.022% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock SLNO or ACAD?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or ACAD?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Soleno Therapeutics, Inc.'s net income of $26M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 25.45x versus 4.41x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.25.45x -- $66M $26M ACADACADIA Pharmaceuticals, Inc.4.41x 17.66x $278.6M $71.8M
-
Which has Higher Returns SLNO or ACTU?
Actuate Therapeutics, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of --. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Actuate Therapeutics, Inc.'s return on equity of -1392.96%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M ACTUActuate Therapeutics, Inc.-- -$0.25 $11.3M -
What do Analysts Say About SLNO or ACTU?
Soleno Therapeutics, Inc. has a consensus price target of $113.54, signalling upside risk potential of 121.02%. On the other hand Actuate Therapeutics, Inc. has an analysts' consensus of $25.03 which suggests that it could grow by 240.54%. Given that Actuate Therapeutics, Inc. has higher upside potential than Soleno Therapeutics, Inc., analysts believe Actuate Therapeutics, Inc. is more attractive than Soleno Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 ACTUActuate Therapeutics, Inc.4 0 0 -
Is SLNO or ACTU More Risky?
Soleno Therapeutics, Inc. has a beta of -3.150, which suggesting that the stock is 415.022% less volatile than S&P 500. In comparison Actuate Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SLNO or ACTU?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actuate Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Actuate Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or ACTU?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than Actuate Therapeutics, Inc. quarterly revenues of --. Soleno Therapeutics, Inc.'s net income of $26M is higher than Actuate Therapeutics, Inc.'s net income of -$5.4M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Actuate Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 25.45x versus -- for Actuate Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.25.45x -- $66M $26M ACTUActuate Therapeutics, Inc.-- -- -- -$5.4M
-
Which has Higher Returns SLNO or AGL?
Agilon Health, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -7.68%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Agilon Health, Inc.'s return on equity of -71.4%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M AGLAgilon Health, Inc.-5.23% -$0.27 $343.2M -
What do Analysts Say About SLNO or AGL?
Soleno Therapeutics, Inc. has a consensus price target of $113.54, signalling upside risk potential of 121.02%. On the other hand Agilon Health, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 47.96%. Given that Soleno Therapeutics, Inc. has higher upside potential than Agilon Health, Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than Agilon Health, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 AGLAgilon Health, Inc.2 14 0 -
Is SLNO or AGL More Risky?
Soleno Therapeutics, Inc. has a beta of -3.150, which suggesting that the stock is 415.022% less volatile than S&P 500. In comparison Agilon Health, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SLNO or AGL?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agilon Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Agilon Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or AGL?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are smaller than Agilon Health, Inc. quarterly revenues of $1.4B. Soleno Therapeutics, Inc.'s net income of $26M is higher than Agilon Health, Inc.'s net income of -$110.2M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Agilon Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 25.45x versus 0.05x for Agilon Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.25.45x -- $66M $26M AGLAgilon Health, Inc.0.05x -- $1.4B -$110.2M
-
Which has Higher Returns SLNO or MRK?
Merck & Co., Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of 33.68%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About SLNO or MRK?
Soleno Therapeutics, Inc. has a consensus price target of $113.54, signalling upside risk potential of 121.02%. On the other hand Merck & Co., Inc. has an analysts' consensus of $106.62 which suggests that it could grow by 6.92%. Given that Soleno Therapeutics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Soleno Therapeutics, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 MRKMerck & Co., Inc.14 13 0 -
Is SLNO or MRK More Risky?
Soleno Therapeutics, Inc. has a beta of -3.150, which suggesting that the stock is 415.022% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.
-
Which is a Better Dividend Stock SLNO or MRK?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.81 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SLNO or MRK?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Soleno Therapeutics, Inc.'s net income of $26M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 25.45x versus 3.93x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.25.45x -- $66M $26M MRKMerck & Co., Inc.3.93x 13.19x $17.2B $5.8B
-
Which has Higher Returns SLNO or RCEL?
AVITA Medical, Inc. has a net margin of 39.4% compared to Soleno Therapeutics, Inc.'s net margin of -77.29%. Soleno Therapeutics, Inc.'s return on equity of -26.56% beat AVITA Medical, Inc.'s return on equity of -1112.54%.
Company Gross Margin Earnings Per Share Invested Capital SLNOSoleno Therapeutics, Inc.98.27% $0.47 $547.5M RCELAVITA Medical, Inc.81.32% -$0.46 $38.1M -
What do Analysts Say About SLNO or RCEL?
Soleno Therapeutics, Inc. has a consensus price target of $113.54, signalling upside risk potential of 121.02%. On the other hand AVITA Medical, Inc. has an analysts' consensus of $7.92 which suggests that it could grow by 125.29%. Given that AVITA Medical, Inc. has higher upside potential than Soleno Therapeutics, Inc., analysts believe AVITA Medical, Inc. is more attractive than Soleno Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SLNOSoleno Therapeutics, Inc.11 0 0 RCELAVITA Medical, Inc.3 2 1 -
Is SLNO or RCEL More Risky?
Soleno Therapeutics, Inc. has a beta of -3.150, which suggesting that the stock is 415.022% less volatile than S&P 500. In comparison AVITA Medical, Inc. has a beta of 1.658, suggesting its more volatile than the S&P 500 by 65.807%.
-
Which is a Better Dividend Stock SLNO or RCEL?
Soleno Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics, Inc. pays -- of its earnings as a dividend. AVITA Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNO or RCEL?
Soleno Therapeutics, Inc. quarterly revenues are $66M, which are larger than AVITA Medical, Inc. quarterly revenues of $17.1M. Soleno Therapeutics, Inc.'s net income of $26M is higher than AVITA Medical, Inc.'s net income of -$13.2M. Notably, Soleno Therapeutics, Inc.'s price-to-earnings ratio is -- while AVITA Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics, Inc. is 25.45x versus 1.30x for AVITA Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNOSoleno Therapeutics, Inc.25.45x -- $66M $26M RCELAVITA Medical, Inc.1.30x -- $17.1M -$13.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
